可吸入的基于脂质的纳米载体被聚多巴胺覆盖,用于有效的粘液透和肺部保留
Xiaobo Zhang1, Zhengli Zhou1, Xiaohui Yang1
1State Key Laboratory of Functions and Applications of Medicinal Plants, School of Pharmaceutical Sciences, Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang 561113, China.
聚多巴胺 (PDA) 涂层增强了吸入纳米载体的粘液透和肺部保留,为肺部药物输送提供了一个有希望的策略. 这种表面修饰提高了纳米载体在治疗肺部疾病中的性能.
科学领域:
- 纳米技术纳米技术
- 材料科学 材料科学 材料科学
- 肺部药物输送 肺部药物输送
背景情况:
- 肺部药物输送面临着粘液屏障和短时间的肺保留时间的挑战.
- 吸入式纳米载体需要表面修改以提高治疗效果.
研究的目的:
- 研究聚多巴胺 (PDA) 作为可吸入脂基纳米载体的表面修饰剂.
- 与聚乙烯糖醇 (PEG) 相比,评估PDA对粘液透和肺部保留的影响.
主要方法:
- 用PDA涂层的脂质纳米乳液,固体脂质纳米颗粒和脂质体的制备.
- 评估纳米载体与粘素和粘液透性的相互作用.
- 评价肺部保留和呼吸细胞的细胞吸收.
主要成果:
- PDA涂层的纳米载体显示减少了粘素相互作用,增强了粘液透,并改善了细胞吸收.
- PDA涂层改善了脂质纳米乳液 (<50 nm) 和固体脂质纳米颗粒 (<100 nm) 的肺保留.
- 与PDA涂层相比,PEG化脂质体 (∼150nm) 显示出较高的肺保留率,可能是由于巨细胞相互作用.
结论:
- 聚多巴胺是可吸入纳米载体的有希望的表面修饰剂,增强粘液透.
- 对于特定的纳米载体类型和尺寸,PDA涂层可以改善肺部保留.
- 表面修饰策略对于优化吸入纳米载体治疗肺部疾病至关重要.
更多相关视频
10:16Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
Published on: February 8, 2017
07:28Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
相关概念视频
Inhaled Medications
Drug Delivery: Miscellaneous Routes
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Drugs Used in Upper Respiratory Disorders: Overview
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Additional Routes of Drug Administration
Administering drugs via inhalation allows for the direct delivery of gaseous, volatile substances or droplets to different parts of the respiratory tract. One of the advantages of the inhalation route is the rapid absorption of drugs into the circulatory system, which is possible because of the large surface area of...
Non-Oral Extravascular Drug Absorption Routes
Lipophilic drugs that are stable at salivary pH (6) and exhibit minimal binding to the oral mucosa are absorbed more...
